Wegovy U — what the label means and why it matters for your treatment

You've seen 'Wegovy U' on a label, here's what's actually going on

Picture this: you've received a Wegovy prescription, or you're researching the medicine before a consultation, and you keep seeing 'U' tacked on. It's easy to assume it marks some special variant or that you've missed something important. In almost every UK context, it hasn't. The 'U' notation appears in prescribing and dispensing records as shorthand for unit or units, a convention carried over from broader pharmacy documentation practice, particularly in electronic prescription systems. It is not a distinct product code, not a separate licence category, and not a signal that one 'U' version is safer or stronger than another.

What matters far more than that single letter is the strength and pen format written on your prescription. Wegovy comes as a pre-filled once-weekly injection pen, with dose strengths of 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg. A newer 7.2 mg dose, approved by the MHRA in April 2026, adds a further option for eligible adults. Your prescriber moves you through these steps over months, the full titration schedule for Wegovy is what genuinely shapes your treatment, not the letter that follows the name on a label.

If you're ever unsure about what a notation on your prescription means, the right person to ask is your prescriber or dispensing pharmacist, not a search engine. Prescription shorthand can vary between systems, and your own clinical record is what counts.

The semaglutide behind the brand name, and why the dose ladder exists

Wegovy's active ingredient is semaglutide, a GLP-1 receptor agonist that works by mimicking a gut hormone released after eating. It slows the rate at which the stomach empties, reduces appetite signals, and supports the feeling of fullness after smaller meals. This is a biological mechanism, not a willpower intervention, a distinction that matters for anyone who's spent years being told they just need to try harder.

The stepped dose schedule (beginning at 0.25 mg) is not a therapeutic dose in the usual sense. That starting level exists to let your body adapt, keeping early side effects manageable while the treatment builds towards its effective range. The 1.0 mg phase sits roughly in the middle of the journey, with 2.4 mg being the established maintenance dose for most people. Clinical trial data published in the New England Journal of Medicine (STEP 1, 68 weeks) showed an average body-weight reduction of around 15% at the 2.4 mg dose alongside lifestyle changes, figures that inform what NICE and NHS England use when assessing the medicine's value.

A common misconception is that a higher dose always means better or faster results. In practice, titration is about tolerability as much as efficacy. Moving too fast through the schedule tends to increase gastrointestinal side effects without proportionally improving outcomes. Your prescriber decides the pace, informed by how you're responding, the 0.5 mg step is a good example of a stage that some people move through quickly and others hold at for a little longer, depending on how they feel.

Who Wegovy is licensed for, and the clinical picture prescribers consider

In the UK, Wegovy is licensed for adults with a BMI of 30 or above, or a BMI of 27–29.9 where at least one weight-related condition is present, such as high blood pressure, raised cholesterol, type 2 diabetes, or obstructive sleep apnoea. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance. The full overview of Wegovy's UK licence covers eligibility in detail, including how NHS and private access routes differ.

NICE's appraisal of semaglutide for weight management (TA875) restricts NHS-funded access to specialist services and sets a two-year maximum treatment duration under that funding route. Private prescribing follows the licensed criteria rather than NICE's funding conditions, which is why a regulated private pharmacy can prescribe it to a wider group of eligible adults, provided the clinical assessment supports it. If you're exploring your options, comparing weight-loss treatments available in the UK may help clarify where Wegovy fits alongside other licensed medicines.

Wegovy is not suitable during pregnancy, while breastfeeding, or if you are actively trying to conceive. It is not licensed for anyone under 18. Certain conditions (including a personal or family history of medullary thyroid carcinoma, or a history of pancreatitis) require careful prescriber discussion before treatment begins. The NHS's patient-level guidance on semaglutide, available on nhs.uk, sets out these considerations clearly.

Side effects, the MHRA's monitoring role, and when to seek help

The most commonly reported side effects with Wegovy are gastrointestinal: nausea, loose stools, constipation, indigestion, and burping tend to cluster around dose increases and usually settle within a couple of weeks as the body adjusts. Headache, fatigue, and mild dizziness are also reported. Most people find the effects are at their worst in the first few days after a new dose level and ease significantly after that.

There are some symptoms that warrant prompt medical attention. Severe stomach pain that extends through to the back (particularly if persistent and accompanied by vomiting) should be assessed urgently, as it may indicate pancreatitis. The MHRA highlighted acute pancreatitis as a known infrequent but serious risk with GLP-1 medicines in a Drug Safety Update in January 2026; the same link lets patients report any suspected side effects directly. Signs of a serious allergic reaction, including swelling of the face or throat, also require emergency care.

If you're weighing up costs as part of your decision, our cost context page for Wegovy explains what private treatment pricing reflects and what's included in a single transparent price. When you're ready to speak with someone, you can speak to our prescribers through a free consultation, reviewed the same day by a GPhC-registered Independent Prescriber.